Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Rapid Dose Therapeutics Corp. is a Canada-based pharmaceutical technology company focused on the development and licensing of proprietary drug delivery platforms for oral thin film and oral dissolvable formulations. The company operates within the pharmaceuticals, biotechnology, and drug delivery technology industries, with an emphasis on improving bioavailability, dosing accuracy, and patient compliance for both prescription and over-the-counter therapeutics.
The company’s core value proposition centers on its proprietary QuickStrip™ technology, an orally dissolvable thin film designed to deliver active pharmaceutical ingredients rapidly without the need for water. Rapid Dose Therapeutics has positioned itself primarily as a technology licensor and development partner rather than a fully integrated pharmaceutical manufacturer. Founded in Canada in the early 2010s, the company evolved from formulation research into a platform-based business model targeting pharmaceutical, nutraceutical, and cannabis-derived product markets.
Business Operations
Rapid Dose Therapeutics generates revenue primarily through technology licensing, development agreements, and formulation services related to its QuickStrip™ and related oral delivery platforms. Its operations focus on research and development, intellectual property management, and collaboration with third-party manufacturers and brand owners. The company does not operate large-scale commercial manufacturing facilities and instead relies on external production partners for commercialization.
The company’s activities are concentrated in product formulation, clinical validation support, and regulatory pathway development for partners seeking to use its delivery technology. Public disclosures indicate limited commercial revenue to date, with operations historically supported by equity financing and strategic agreements. Data inconclusive based on available public sources regarding the scale and consistency of recurring revenue streams.
Strategic Position & Investments
Strategically, Rapid Dose Therapeutics aims to expand adoption of its oral thin film technology across multiple therapeutic categories, including pain management, central nervous system indications, nutraceuticals, and cannabinoid-based products. Growth initiatives have focused on signing licensing and development agreements with pharmaceutical and consumer health companies rather than pursuing independent drug commercialization.
The company has disclosed investments primarily in intellectual property development, formulation science, and regulatory readiness. There is no verified public evidence of major acquisitions or controlling interests in operating subsidiaries beyond its core technology assets. While the company has referenced potential applications in emerging delivery formats, data inconclusive based on available public sources regarding material investments in advanced biologics or novel drug classes.
Geographic Footprint
Rapid Dose Therapeutics is headquartered in Canada, with its primary corporate, research, and administrative activities conducted domestically. The company’s market strategy is international in scope, targeting licensing partners in North America, Europe, and select global pharmaceutical markets.
Operational influence outside Canada is largely indirect, achieved through intellectual property protection, cross-border licensing agreements, and collaborations rather than owned facilities or subsidiaries. There is no verified public disclosure of permanent operational sites or manufacturing assets outside Canada.
Leadership & Governance
Rapid Dose Therapeutics was founded by Mark Upsdell, who has played a central role in shaping the company’s technology-driven strategy and early-stage development. The leadership team emphasizes capital efficiency, platform scalability, and partnership-led growth, reflecting the company’s positioning as a technology provider rather than a product-centric pharmaceutical firm.
Key executives include:
- Mark Upsdell – Founder and Chief Executive Officer
- Michael Young – Chief Financial Officer
- Paul Sullivan – Chief Operating Officer
The board and executive leadership oversee corporate governance, capital allocation, and strategic partnerships, with a stated focus on protecting intellectual property and expanding the commercial relevance of the QuickStrip™ platform across regulated health markets.